Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Urticaria 1Sarcoma 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Mastocytosis 1Histiocytoma, Malignant Fibrous 1Colorectal Neoplasms 1Angioedemas, Hereditary 1Angioedema 1Adenoma, Islet Cell 1

Interventions

Radiation Dose Hypofractionation 2toripalimab 1lentiviral minigene vaccine of COVID-19 coronavirus 1envafolimab 1brostallicin 1anlotinib 1Temozolomide 1Ritonavir 1Radiotherapy 1Phlebotomy 1Molecular Diagnostic Techniques 1Microarray Analysis 1Ipilimumab 1Indinavir 1Doxorubicin 1Diathermy 1Blood Specimen Collection 1Biopsy, Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Histiocytoma, Malignant Fibrous × Phlebotomy × Clear all
NCT03946943 2019-07-10

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

The First Hospital of Jilin University

Phase 2 Unknown
25 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡